Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficient α and β- radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model.
Ceuppens H, Pombo Antunes AR, Navarro L, Ertveldt T, Berdal M, Nagachinta S, De Ridder K, Lahoutte T, Keyaerts M, Devoogdt N, Goyvaerts C, D'Huyvetter M, Breckpot K. Ceuppens H, et al. Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):444-457. doi: 10.1007/s00259-024-06914-4. Epub 2024 Sep 6. Eur J Nucl Med Mol Imaging. 2025. PMID: 39237746
Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade.
Awad RM, Lecocq Q, Zeven K, Ertveldt T, De Beck L, Ceuppens H, Broos K, De Vlaeminck Y, Goyvaerts C, Verdonck M, Raes G, Van Parys A, Cauwels A, Keyaerts M, Devoogdt N, Breckpot K. Awad RM, et al. Among authors: ceuppens h. Mol Ther Methods Clin Dev. 2021 Jun 4;22:172-182. doi: 10.1016/j.omtm.2021.05.017. eCollection 2021 Sep 10. Mol Ther Methods Clin Dev. 2021. PMID: 34485603 Free PMC article.
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.
Ertveldt T, De Beck L, De Ridder K, Locy H, de Mey W, Goyvaerts C, Lecocq Q, Ceuppens H, De Vlaeminck Y, Awad RM, Keyaerts M, Devoogdt N, D'Huyvetter M, Breckpot K, Krasniqi A. Ertveldt T, et al. Among authors: ceuppens h. Mol Cancer Ther. 2022 Jul 5;21(7):1136-1148. doi: 10.1158/1535-7163.MCT-21-0791. Mol Cancer Ther. 2022. PMID: 35499391 Free PMC article.
Emerging applications of nanobodies in cancer therapy.
Awad RM, Meeus F, Ceuppens H, Ertveldt T, Hanssens H, Lecocq Q, Mateusiak L, Zeven K, Valenta H, De Groof TWM, De Vlaeminck Y, Krasniqi A, De Veirman K, Goyvaerts C, D'Huyvetter M, Hernot S, Devoogdt N, Breckpot K. Awad RM, et al. Among authors: ceuppens h. Int Rev Cell Mol Biol. 2022;369:143-199. doi: 10.1016/bs.ircmb.2022.03.010. Epub 2022 May 18. Int Rev Cell Mol Biol. 2022. PMID: 35777863
Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment.
Ertveldt T, Krasniqi A, Ceuppens H, Puttemans J, Dekempeneer Y, Jonghe K, Mey W, Lecocq Q, Vlaeminck Y, Awad RM, Goyvaerts C, Veirman K, Morgenstern A, Bruchertseifer F, Keyaerts M, Devoogdt N, D'Huyvetter M, Breckpot K. Ertveldt T, et al. Among authors: ceuppens h. J Nucl Med. 2023 May;64(5):751-758. doi: 10.2967/jnumed.122.264752. Epub 2023 Apr 13. J Nucl Med. 2023. PMID: 37055223 Free article.
Generic semi-automated radiofluorination strategy for single domain antibodies: [18F]FB-labelled single domain antibodies for PET imaging of fibroblast activation protein-α or folate receptor-α overexpression in cancer.
Dierick H, Navarro L, Ceuppens H, Ertveldt T, Pombo Antunes AR, Keyaerts M, Devoogdt N, Breckpot K, D'Huyvetter M, Lahoutte T, Caveliers V, Bridoux J. Dierick H, et al. Among authors: ceuppens h. EJNMMI Radiopharm Chem. 2024 Jul 24;9(1):54. doi: 10.1186/s41181-024-00286-8. EJNMMI Radiopharm Chem. 2024. PMID: 39048805 Free PMC article.
28 results